DOCSLIB.ORG

Prochlorperazine — the Forgotten Antiemetic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prochlorperazine — the Forgotten Antiemetic Volume 23, Number 6 June 2009 Drugs & Therapy B N U N L N L N E N T N I N N MEDICATION SAFETY FORMULARY UPDATE The Pharmacy and Therapeutics Prochlorperazine — Committee met May 19, 2009. No drugs were added in the Formulary while 1 was deleted. 9 drugs or dos- the forgotten antiemetic age forms were designated nonfor- mulary and not available. Criteria ata from 2006 attributed 3.7% of and to reduce narcotic requirement in were changed for 6 drugs, including D Emergency Department (ED) visits some surgical situations. 2 exceptions to “contraindications.” to nausea and vomiting, which was the Although phenothiazines like pro- 4th most common reason for an ED visit. chlorperazine and promethazine are Nausea and/or vomiting are the result in the same general pharmacologic ◆ ADDED of peripheral or central stimulation of class, they do not have identical pri- None the chemoreceptor trigger zone (CTZ). mary mechanism of actions or adverse Precipitating factors include ingestion events. Prochlorperazine blocks post- of medications or toxins, infection, gas- synaptic mesolimbic dopaminergic D1- ◆ DELETED - trointestinal obstruction, gastroparesis, and D2 receptors, which includes the Lomustine (CeeNu® Dosepack)* pregnancy, migraines, and surgical CTZ, explaining its antiemetic effect. *Nonformulary and must be ordered procedures. Treatment options are usu- Prochlorperazine also has moderate on Chemotherapy Order Form ally described as 2 broad categories: anticholinergic and alpha-adrenergic antiemetics and prokinetics. Antiemet- receptor-blocking activity. Prometha- ics include phenothiazines, antihis- zine is primarily a competitive hista- ◆ NONFORMULARY AND tamines, anticholinergics, dopamine mine1-receptor blocker with muscarinic NOT AVAILABLE antagonists, and 5-HT3 antagonists. M1-receptor-blocking activity resulting Darifenacin Prokinetic agents used for dysmotility in antihistaminic, sedative, anti-mo- (Enablex® by Novartis)† syndromes include metoclopramide tion-sickness, antiemetic, and anticho- Fesoterodine (Toviaz® by Pfizer)† and erythromycin. linergic properties. Phenothiazines, specifically prochlor- Despite proven efficacy, these medi- Flavoxate (Generic)† perazine and promethazine, are often cations are not without risks. As recent Oxybutynin ER overlooked with the presence of newer, as March 2009, promethazine was the (Ditropan® XL by Ortho)† more heavily promoted antiemetic center of a US Supreme Court decision agents like 5-HT3 antagonists (eg, about product liability. In 2000, a musi- Oxybutynin Transdermal ondansetron). However, these agents cian went to the emergency room for ® (Oxytrol by WatsonPharma)‡ should not be disregarded. The 5-HT3 a migraine with nausea. She received ‡Prescriber must change to tolterodine antagonists are used mainly for preven- meperidine and promethazine intra- ER or oxybutynin IR tion of nausea. Clinical experience sug- venously (IV). At the site of infusion, gests that 5-HT antagonists are not as she developed gangrene that required Solifenacin 3 effective once a patient is vomiting. amputation of the forearm.1 Intrave- (Vesicare® by GlaxoSmithKline)† Promethazine was developed in the nous preparations of pro methazine Tolterodine IR (Detrol® by Pfizer)† 1930s, followed by prochlorperazine have a pH between 4 and 5.5. At this in the 1950s. Initially developed for pH, the surrounding tissue can become Trospium IR/ER anesthesia and antipsychotic use, severely damaged if extravasation from (Sanctura®/XR by Allergan)† these agents were later found to have the IV site occurs. We have previously †Interchanged to tolterodine ER antiemetic effects. Over time, anti- cautioned about this potential problem emetic use became their principal place in the Bulletin. Also, cautionary alerts ◆ INTERCHANGES in therapy. Not only are phenothiazines warning nurses to dilute the vial into effective, there are multiple dosage (continued on page 6) Tolterodine ER (Detrol® LA) for forms available, from oral formulations Darifenacin (Enablex®) to suppositories and parenteral routes. Tolterodine ER (Detrol® LA) for Prochlorperazine has labeled indica- ◆ Fesoterodine (Toviaz®) tions for the control of severe nausea INSIDE THIS ISSUE and vomiting as well as treatment of Tolterodine ER (Detrol® LA) for schizophrenia. Promethazine is labeled ◆ Flavoxate (Generic) Use Cockcroft-Gault for renal dosing for the treatment of active motion sick- ness, prevention of postoperative nau- ◆ Ceftriaxone + calcium (continued on next page) sea and vomiting, allergic reactions, ◆ CRITERIA-FOR-USE CHANGES (cont.) Formulary update, from page 1 THERAPEUTIC INTERCHANGE OF OAB AGENTS Interchanged to Tolterodine ER 2 mg daily ◆ INTERCHANGES (cont.) Tolterodine IR 1 mg twice a day Oxybutynin ER 5 mg daily Darifenacin 7.5 mg daily Solifenacin 5 mg daily Tolterodine ER (Detrol® LA) for Trospium IR 20 mg daily Flavoxate 100 mg 3-4 times/day Oxybutynin ER (Ditropan® XL) Tolterodine ER (Detrol® LA) for Interchanged to Tolterodine ER 4 mg daily Solifenacin (Vesicare®) Tolterodine IR 2 mg twice a day Oxybutynin ER 10-30 mg daily Darifenacin 15 mg daily Solifenacin 10 mg daily Tolterodine ER (Detrol® LA) for Trospium IR 20 mg twice a day Trospium ER 60 mg daily Tolterodine IR (Detrol®) Flavoxate 200 mg 3-4 times/day Fesoterodine 4-8 mg daily Tolterodine ER (Detrol® LA) for ® OAB may affect quality of life for some the stimulation of clotting factors (ie, fac- Trospium ER (Sanctura XR) patients and is characterized by symp- tor VIII and von Willebrand factor [vWF]). Tolterodine ER (Detrol® LA) for toms of frequency and urgency, with or DDAVP has labeled indications for Trospium IR (Sanctura®) without urge incontinence. Antimusca- diabetes insipidus, enuresis, and rinic agents are first-line pharmacological bleeding in patients with hemophilia ◆ CRITERIA-FOR-USE CHANGES options for OAB. There are 6 marketed or von Willebrand’s disease. It is used antimuscarinic drugs with labeled indi- off-label for various uses including ure- Desmopressin Injection (DDAVP cations for the treatment of OAB. Flavox- mic bleeding. Patients with advanced [Generic])§ ate is used off-label for OAB. kidney disease are predisposed to §Use for uremic bleeding permitted There is no consensus on the preferred bleeding because of platelet dysfunc- agent for the treatment of OAB. Oxybu- tion. DDAVP improves platelet func- ® Dofetilide (Tikosyn by Pfizer)¶ tynin IR tablets and syrup and tolterodine tion, presumably because it stimulates ¶Dofetilide Order Form required ER capsules have been listed in the For- vWF. Everolimus mulary. Over the past year, there has been According to the official labeling, (Afinitor® by Novartis)** little use of the other agents in this class. DDAVP use is contraindicated in The comparative efficacy and safety of patients with a creatinine clearance **Chemotherapy Order Form required the various antimuscarinic agents used less than 50 mL/min. The clearance of Heparin, Unfractionated for OAB have been evaluated in system- DDAVP is reduced, which may cause (Generic)†† atic reviews and meta-analyses. The an unexpected degree of water ac- most recent and comprehensive of these cumulation leading to hyponatremia. ††Saline used to flush central catheters reviews show no significant difference However, there are instances in which in efficacy among the antimuscarinic it may be appropriate to use DDAVP in Linezolid (Zyvox® by Pfizer)‡‡ agents for OAB. ER products may be pre- patients with kidney disease. ‡‡Use with sympathomimetics per- ferred over IR products in patients who Uremic bleeding typically presents mitted in monitored units; Progress experience adverse reactions (ADRs). In with ecchymoses, purpura, epistaxis, Note required for use with antide- clinical trials, patients treated with tolt- and bleeding from venipuncture pressants erodine ER rarely discontinued therapy sites. These patients can also present Oseltamivir because of ADRs. with gastrointestinal or intracranial (Tamiflu® by Roche)§§ Detrol® LA is the most commonly bleeding. Because DDAVP normalizes prescribed drug used to treat OAB. It bleeding time in 75% of patients with §§Restricted to ID physician approval is the 66th most common prescription chronic renal failure, it is the most in community pharmacies (ie, 5.6 mil- common agent used in active uremic Lomustine is an oral alkylating lion prescriptions). Tolterodine ER was bleeding. DDAVP doses for uremic agent marketed since 1976 that is selected to represent OAB drugs so that bleeding are approximately 10-fold used to treat Hodgkin’s disease and the fewest number of interchanges will higher than doses used for diabetes brain tumors. The CeeNU® Dose-Pack, be necessary. insipidus (0.3 mcg/kg to 0.4 mcg/kg which contained 10-, 40-, and 100-mg Oxybutynin IR tablet and syrup remain IV or SQ as a single injection). An capsules, is no longer available. Only in the Formulary for patients taking it as important advantage of DDAVP is its the individual capsule strengths are a home medication and for patients un- rapid onset of action for acute bleeding available. able to take oral solid dosage forms. caused by uremic platelet dysfunction. Lomustine has not been used at Desmopressin is a synthetic analog Studies have shown that DDAVP Shands at UF for several years. There- of the endogenous hormone arginine decreases bleeding time within an fore, it was deleted from the Formu- vasopressin, which is often referred to hour after injection. Alternative op- lary. If ordered nonformulary, it still as DDAVP. DDAVP® is a brand name, but tions
Load more

Recommended publications
  • Prochlorperazine 5Mg Tablets
    Package leaflet: Information for the patient Prochlorperazine 5mg tablets Read all of this leaflet carefully before you start taking this • the person is a child. This is because children may develop unusual face and body medicine, because it contains important information for you. movements (dystonic reactions) • Keep this leaflet. You may need to read it again. • you are diabetic or have high levels of sugar in your blood (hyperglycaemia). Your doctor • If you have any further questions, ask your doctor or pharmacist. may want to monitor you more closely. • This medicine has been prescribed for you only. Do not pass it on to If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before others. It may harm them, even if their signs of illness are the same taking Prochlorperazine Tablets. as yours. Other medicines and Prochlorperazine tablets • If you get any side effects, talk to your doctor or pharmacist. Tell your doctor or pharmacist if you are taking, have recently taken or might take any This includes any possible side effects not listed in this leaflet. other medicines. This includes medicines you buy without a prescription, including herbal See section 4. medicines. This is because Prochlorperazine Tablets can affect the way some other medicines work. What is in this leaflet: Also some medicines can affect the way Prochlorperazine Tablets work. 1 What Prochlorperazine tablets are and what they In particular, tell your doctor if you are taking any of the following: • medicines to help you sleep
    [Show full text]
  • Management of Major Depressive Disorder Clinical Practice Guidelines May 2014
    Federal Bureau of Prisons Management of Major Depressive Disorder Clinical Practice Guidelines May 2014 Table of Contents 1. Purpose ............................................................................................................................................. 1 2. Introduction ...................................................................................................................................... 1 Natural History ................................................................................................................................. 2 Special Considerations ...................................................................................................................... 2 3. Screening ........................................................................................................................................... 3 Screening Questions .......................................................................................................................... 3 Further Screening Methods................................................................................................................ 4 4. Diagnosis ........................................................................................................................................... 4 Depression: Three Levels of Severity ............................................................................................... 4 Clinical Interview and Documentation of Risk Assessment...............................................................
    [Show full text]
  • Louisiana Fee-For-Service Medicaid Antipsychotics
    Louisiana Fee-for-Service Medicaid Antipsychotics The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request: Authorization for non-preferred agents for recipients 6 years of age and older; AND Authorization for all preferred and non-preferred agents for recipients younger than 6 years of age; AND Authorization to exceed maximum daily dose/quantity limit for all ages. See full prescribing information for individual agents for details on the information below: *These agents have Black Box Warnings †These agents are subject to Risk Evaluation and Mitigation Strategy (REMS) under FDA safety regulations ‡ For long-acting injectable agents, it is required that the previous 60-day period of pharmacy claims show one of the following: Established tolerance to the oral formulation (as evidenced by a paid pharmacy claim for the oral formulation); OR Established therapy with the requested injectable agent (as evidenced by a paid pharmacy claim for the requested injectable agent) NOTE: Diagnosis code requirements apply to both preferred and non-preferred agents (see Table 1). Maximum daily dose edits (see Table 2), quantity limits (see Table 3), and other requirements at Point-of-Sale for select agents in this category may apply to both preferred and non-preferred agents. For additional information, see http://www.lamedicaid.com/provweb1/Pharmacy/pharmacyindex.htm. Oral Antipsychotics – Generic Name (Brand Example) * Amitriptyline/Perphenazine * Aripiprazole ODT; Oral Solution (Abilify®); Tablet (Abilify®)
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • Stemzine® (Prochlorperazine Maleate) Tablet
    AUSTRALIAN PRODUCT INFORMATION – STEMZINE® (PROCHLORPERAZINE MALEATE) TABLET 1 NAME OF THE MEDICINE Prochlorperazine maleate. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Stemzine contains 5mg prochlorperazine maleate as the active ingredient. Excipients of known effect: wheat starch (gluten). For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Stemzine 5 mg tablets are off-white to pale cream coloured circular tablets, not more than slightly mottled or specked, one side impressed with 'S' and reverse face plain. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nausea and vomiting due to various causes including migraine; vertigo due to Meniere's syndrome, labyrinthitis and other causes. 4.2 DOSE AND METHOD OF ADMINISTRATION Nausea and vomiting Adults Dosage should be adjusted to suit the response of the individual, beginning with lowest recommended dosage. Oral: 5 or 10 mg two or three times daily. Acute: 20 mg at once, followed, if necessary by 10 mg two hours later. Children (See Section 4.4 Special warnings and precautions for use, Paediatric Use). stem-ccsiv5-piv19-04jun21 Page 1 of 16 If it is considered unavoidable to use prochlorperazine for a child, the dosage is 250 micrograms/kg bodyweight two or three times a day. Prochlorperazine has been associated with dystonic reactions particularly after a cumulative dosage of 500 micrograms/kg. It should therefore be used cautiously in children. Prochlorperazine is not recommended for children weighing less than 10 kg. When treating children, it is recommended that the 5 mg tablets are used. Vertigo and meniere’s disease Adults Oral: 5 to 10 mg three or four times daily.
    [Show full text]
  • 207533Orig1s000
    ( CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207533Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management Risk Evaluation and Mitigation Strategy (REMS) Review Date: October 2, 2015 Reviewer(s): Cathy A. Miller, MPH, B.SN Risk Management Analyst Division of Risk Management Team Leader Kimberly Lehrfeld, Pharm.D. Division of Risk Management Acting Deputy Division Reema Mehta, Pharm.D., MPH Director Division of Risk Management Drug Name(s): Aristada (aripiprazole lauroxil) extended-release injection Therapeutic Class: Atypical Antipsychotic Dosage and Route: 441 mg/1.6 mL; 662 mg/2.4 mL; 882 mg/3.2mL intramuscular injection Application Type/Number: NDA 207533 Submission Number: ORIG-1 Submission Seq. No. 0000 dated August 22, 2014 Applicant/Sponsor: Alkermes OSE RCM #: 2014-1849 ***This document contains proprietary and confidential information that should not be released to the public*** Reference ID: 3828483 CONTENTS 1 INTRODUCTION ....................................................................................................... 1 1.1 Product Background............................................................................................ 1 1.2 Disease Background............................................................................................ 2 1.3 Regulatory History .............................................................................................
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • 207533Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207533Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 207553 Priority or Standard Standard Submit Date(s) 8/22/2014 Received Date(s) 8/22/2014 PDUFA Goal Date 8/22/2015 Division / Office DPP/ODE1 Reviewer Name(s) Lucas Kempf, MD Review Completion Date October 2, 2015 Established Name Aripiprazole lauroxil (Proposed) Trade Name Aristada Therapeutic Class Antipsychotic Applicant Alkermes Inc. Formulation(s) Extended release injection Dosing Regimen Suspension/ IM up to 6 weeks Indication(s) Schizophrenia Intended Population(s) Schizophrenia Template Version: March 6, 2009 Reference ID: 3806701 Clinical Review Lucas Kempf, MD NDA 207533 Aristada, Aripiprazole lauroxil Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 7 1.1 Recommendation on Regulatory Action ............................................................. 7 1.2 Risk Benefit Assessment .................................................................................... 7 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 8 1.4 Recommendations for Postmarket Requirements and Commitments ................ 8 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 8 2.1 Product Information ............................................................................................ 8 2.2 Currently Available Treatments for Proposed Indications ..................................
    [Show full text]
  • Antipsychotics for Migraines, Cluster Headaches, and Nausea
    Web extra Antipsychotics for migraines, cluster headaches, and nausea Evidence of efficacy for these conditions is limited, and risk of side effects may inhibit use ost evidence supporting antipsychotics as a treat- ment for migraine headaches and cluster head- Maches is based on small studies and chart reviews. Some research suggests antipsychotics may effectively treat nausea but side effects such as akathisia may limit their use. Migraine headaches Antipsychotic treatment of migraines is supported by the theory that dopaminergic hyperactivity leads to migraine headaches (Table 1, page E2). Antipsychotics have been used off-label in migraine patients who do not tolerate triptans or have status migrainosus—intense, debilitating migraine JON KRAUSE FOR CURRENT PSYCHIATRY lasting >72 hours.1 Primarily a result of D2 receptor block- ade, the serotonergic effects of some second-generation anti- Aveekshit Tripathi, MD psychotics (SGAs) may prevent migraine recurrence. The Senior Resident Psychiatry and Behavioral Sciences first-generation antipsychotics (FGAs) prochlorperazine, droperidol, haloperidol, and chlorpromazine have been Matthew Macaluso, DO Assistant Professor, Psychiatry and Behavioral Sciences 1-27 used for migraine headaches (Table 2, page E3). Associate Director, Residency Training Prochlorperazine may be an effective treatment of acute • • • • headaches9 and refractory chronic daily headache.10 Studies show that buccal prochlorperazine is more effective than oral University of Kansas School of Medicine-Wichita Wichita, KS ergotamine tartrate11 and IV prochlorperazine is more effective than IV ketorolac12 or valproate28 for treating acute headache. Evidence suggests that chlorpromazine administered IM2 or IV3 is better than placebo for managing migraine pain. In a study comparing IV chlorpromazine, lidocaine, and dihydroergotamine, patients treated with chlorproma- zine showed more persistent headache relief 12 to 24 hours post-dose.4 In another study, IV chlorpromazine, 25 mg, Current Psychiatry was as effective as IM ketorolac, 60 mg.5 Vol.
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]
  • Randomized Controlled Trial of Ondansetron Vs. Prochlorperazine in Adults in the Emergency Department
    UC Irvine Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health Title Randomized Controlled Trial of Ondansetron vs. Prochlorperazine in Adults in the Emergency Department Permalink https://escholarship.org/uc/item/7d93s2j7 Journal Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 12(1) ISSN 1936-900X Authors Patka, John Wu, Daniel T. Abraham, Prasad et al. Publication Date 2011 License https://creativecommons.org/licenses/by-nc/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Original research Randomized Controlled Trial of Ondansetron vs. Prochlorperazine in Adults in the Emergency Department John Patka, PharmD* * Grady Health System, Atlanta, GA Daniel T. Wu, MD† † Emory University, Atlanta, GA Prasad Abraham, PharmD* ‡ Southern Regional Hospital, Riverdale, GA Richard M. Sobel, MD, MPH‡ Supervising Section Editor: Gregory Moore, MD, JD Submission history: Submitted November 5, 2009; Revision received February 3, 2010; Accepted April 18, 2010. Reprints available through open access at http://escholarship.org/uc/uciem_westjem Objective: To compare the effectiveness of ondansetron and prochlorperazine to treat vomiting. Secondary objectives were the effectiveness of ondansetron and prochlorperazine to treat nausea and their tolerability. Methods: This was a prospective, randomized, active controlled, double-blinded study. Using a convenience sample, patients were randomized to either intravenous ondansetron 4mg (n=32) or prochlorperazine 10mg (n=32). The primary outcome was the percentage of patients with vomiting at 0-30, 31-60, and 61-120 minutes after the administration of ondansetron or prochlorperazine. Secondary outcomes were nausea assessed by a visual analog scale (VAS) at baseline, 0-30, 31-60, and 61-120 minutes after the administration of ondansetron or prochlorperazine and the percentage of patients with adverse effects (sedation, headache, akathisia, dystonia) to either drug.
    [Show full text]
  • Association Between Antipsychotic Agents and Risk of Acute Respiratory Failure in Patients with Chronic Obstructive Pulmonary Disease
    Research JAMA Psychiatry | Original Investigation Association Between Antipsychotic Agents and Risk of Acute Respiratory Failure in Patients With Chronic Obstructive Pulmonary Disease Meng-Ting Wang, PhD; Chen-Liang Tsai, MD; Chen Wei Lin, BS; Chin-Bin Yeh, MD, PhD; Yun-Han Wang, MS, BPharm; Hui-Lan Lin, ADN, RRT Supplemental content IMPORTANCE Acute respiratory failure (ARF) is a life-threatening event that has been linked in case reports to antipsychotic use, but this association lacks population-based evidence. Particular attention should be focused on patients with chronic obstructive pulmonary disease (COPD) regarding this drug safety concern because these patients are prone to ARF and are commonly treated with antipsychotics. OBJECTIVE To determine whether the use of antipsychotics is associated with an increased risk of ARF in patients with COPD. DESIGN, SETTING, AND PARTICIPANTS A population-based case-crossover study analyzing the Taiwan National Health Insurance Research Database was conducted of all patients with COPD, who were newly diagnosed with ARF in hospital or emergency care settings necessitating intubation or mechanical ventilation from January 1, 2000, to December 31, 2011. Patients with prior ARF, lung cancer, and cardiogenic, traumatic, or septic ARF were excluded to analyze idiopathic ARF. The pilot study was conducted from November 1 to December 31, 2013, and full data analysis was performed from October 15, 2015, to November 8, 2016. EXPOSURES The use of antipsychotics was self-compared during days 1 to 14 (the risk period according to previous case reports) and days 75 to 88 (control period) preceding the ARF event or index date. The antipsychotic class, route of administration, and dose were also examined.
    [Show full text]